Quick Answer
BeOne Medicines Ltd. reported Revenue (ASC 606) of $5.34 billion for fiscal year 2025.
BeOne Medicines Ltd. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $5.34B | +40.2% |
| 2024 | $3.81B | +55.0% |
| 2023 | $2.46B | +73.7% |
| 2022 | $1.42B | +20.4% |
| 2021 | $1.18B | +280.8% |
| 2020 | $308.87M | -27.9% |
| 2019 | $428.21M | +116.0% |
| 2018 | $198.22M | -16.8% |
| 2017 | $238.39M | +22179.2% |
| 2016 | $1.07M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.41B | +41.0% | +7.4% |
| June 30, 2025 | $1.32B | +41.6% | +17.7% |
| March 31, 2025 | $1.12B | +48.6% | +11.5% |
| September 30, 2024 | $1.00B | +28.2% | +7.8% |
| June 30, 2024 | $929.17M | +56.1% | +23.6% |
| March 31, 2024 | $751.65M | +67.9% | -3.8% |
| September 30, 2023 | $781.31M | +101.6% | +31.3% |
| June 30, 2023 | $595.26M | +74.3% | +32.9% |
- BeOne Medicines Ltd. showed an increase of +40.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, BeOne Medicines Ltd.’s revenue (asc 606) has grown by 499248.9% (from $1.07 million to $5.34 billion).
- The most recent figure is from BeOne Medicines Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: